Eliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest Update

Eliem Therapeutics, Inc. (NASDAQ:ELYM) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totalling 742,200 shares, a growth of 98.8% from the June 30th total of 373,300 shares. Approximately 1.3% of the shares of the company are sold short. Based on an average daily volume of 307,600 shares, the short-interest ratio is presently 2.4 days.

Insider Transactions at Eliem Therapeutics

In other news, EVP Valerie Morisset sold 69,005 shares of Eliem Therapeutics stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $8.03, for a total transaction of $554,110.15. Following the sale, the executive vice president now owns 31,317 shares in the company, valued at $251,475.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Ra Capital Management, L.P. purchased 13,008,546 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The shares were purchased at an average price of $3.84 per share, for a total transaction of $49,952,816.64. Following the transaction, the director now directly owns 23,521,757 shares of the company’s stock, valued at approximately $90,323,546.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Valerie Morisset sold 69,005 shares of the business’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $8.03, for a total value of $554,110.15. Following the completion of the transaction, the executive vice president now owns 31,317 shares in the company, valued at approximately $251,475.51. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 294,308 shares of company stock worth $2,136,494. Corporate insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On Eliem Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Cerity Partners LLC purchased a new stake in shares of Eliem Therapeutics during the 4th quarter worth approximately $37,000. Bank of New York Mellon Corp purchased a new stake in shares of Eliem Therapeutics during the 2nd quarter worth approximately $134,000. Finally, BML Capital Management LLC boosted its stake in shares of Eliem Therapeutics by 12.5% during the 4th quarter. BML Capital Management LLC now owns 2,180,000 shares of the company’s stock worth $5,886,000 after acquiring an additional 241,737 shares in the last quarter. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Eliem Therapeutics Stock Down 3.9 %

ELYM stock traded down $0.35 during trading on Friday, hitting $8.55. The company had a trading volume of 301,935 shares, compared to its average volume of 453,925. Eliem Therapeutics has a 1-year low of $2.35 and a 1-year high of $11.55. The firm has a 50-day moving average price of $7.70 and a 200-day moving average price of $5.12. The firm has a market cap of $254.36 million, a PE ratio of -16.30 and a beta of -0.33.

Eliem Therapeutics (NASDAQ:ELYM) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.06) earnings per share for the quarter.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.